Crossbow Therapeutics closed a $77 million Series B to advance its T‑cell engager pipeline, the company said. Cambridge, Massachusetts–based Crossbow will use the funds to complete a Phase I trial of CBX‑250, a first‑in‑class T‑bolt T‑cell engager for relapsed or refractory myeloid malignancies, and to progress a second candidate, CBX‑663. CEO Briggs Morrison told BioXconomy the round follows a 2023 Series A and underwrites expansion of the T‑Bolt platform. Crossbow’s T‑Bolt platform engineers antibodies that mimic T‑cell receptors to recognize peptide fragments presented on HLA complexes, enabling targeting of intracellular tumor antigens not reachable by conventional antibodies. The company projects an IND filing for CBX‑663 in spring 2026. Investors and translational teams will watch safety and early activity from CBX‑250’s Phase I readout for signals that the platform can unlock new oncology targets.